Last reviewed · How we verify

Orkedia — Competitive Intelligence Brief

Orkedia (EVOCALCET) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Extracellular calcium-sensing receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Orkedia (EVOCALCET) — Kyowa Hakko Kirin Co., Ltd..

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Orkedia TARGET EVOCALCET Kyowa Hakko Kirin Co., Ltd. marketed Extracellular calcium-sensing receptor
Sensipar CINACALCET Amgen marketed Calcium-sensing Receptor Agonist Extracellular calcium-sensing receptor 2004-01-01
Upasita UPACICALCET SANWA KAGAKU KENKYUSHO Co., Ltd. marketed Extracellular calcium-sensing receptor
L-Tryptophan TRYPTOPHAN marketed tryptophan Myeloperoxidase, Extracellular calcium-sensing receptor, Probable G-protein coupled receptor 139

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Orkedia — Competitive Intelligence Brief. https://druglandscape.com/ci/evocalcet. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: